Shilpa Medicare’s arm gets CEP from EDQM for API, Teriflunomide

23 Jan 2025 Evaluate

Shilpa Medicare’s 100% subsidiary -- Shilpa Pharma Lifesciences has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Teriflunomide. 

Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis (MS). Teriflunomide has demonstrated clinical efficacy and safety in a number of large, multicenter, phase III clinical trials and is an attractive agent to add to the growing repertoire of available treatments for MS, as it has the benefit of oral administration.

This certificate is 25th CEP issued by EDQM to the company, which showcases its continued expertise and commitment to develop, manufacture and supply of quality-oriented products of global standards.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

641.05 17.35 (2.78%)
05-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1581.95
Dr. Reddys Lab 1126.55
Cipla 1418.45
Lupin 2009.65
Zydus Lifesciences 887.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...